ImClone to trim sales forces from 70 reps to 40

Share this article:

ImClone, recently acquired by Lilly for $6.5 billion, will cut 30 of its 70 in-house sales reps. The decision to cut reps, reported by Pharmalot.com, will require Bristol-Myers Squibb – a co-marketer for ImClone's Erbitux cancer medication – and Lilly, to “streamline efforts and create synergies across…field sales organizations for the benefit of the prescribers and patients [ImClone] serves,” a spokesperson told Pharmalot.

“About 30 of the nearly 70 roles that made up the ImClone sales force were eliminated. This takes the overall size of the sales force back to a mid-2007 sales model that proved very effective for ImClone in maximizing the sales of Erbitux.,” the spokesperson told Pharmalot. “[ImClone is] also confident the Bristol-Myers Squibb field sales force focused on supporting Erbitux will continue to contribute to the success of this valuable targeted agent for patients.”

Initial ImClone acquisition talks resulted in a histrionic back and forth between Bristol-Myers Squibb's CEO, Jim Cornelius, and ImClone's chairman Carl Icahn, with Lilly eventually stepping in to offer the highest bid. Lilly's ImClone will join the list of other manufactures trimming sales forces in order to control costs.

A spokesperson at ImClone confirmed statements made to Pharmalot, but would not provide further comment.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...